Search clinical trials for: Placebo (Matching with BMS-919373)

Total 2407 results

Gmax Biopharm Australia Pty Ltd.

Completed

Assessment of the Safety, Tolerability, and Pharmacokinetic of GMA106

Overweight and Obesity

Australia
AstraZeneca

Completed

Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise

Diabetes Mellitus, Type 2

United States, Canada, Mexico, Puerto Rico, Taiwan, Australia
Biogen
Denali Therapeutics Inc.

Recruiting

A Study to Assess the Safety of BIIB122 Tablets and if it Can Slow the Worsening of Early-Stage Parkinson's Disease in Participants Between the Ages of 30 and 80 (LUMA)

Parkinson Disease

United States, Netherlands, Italy, Spain, Israel, Canada, China, Germany, France, Austria, United Kingdom, Poland, Japan
AbbVie

Recruiting

Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)

Migraine

United States, Puerto Rico
Celldex Therapeutics

Active, not recruiting

A Study of CDX-0159 in Patients With Chronic Inducible Urticaria

Chronic Inducible Urticaria

United States, Latvia, Spain, Poland, Georgia, South Africa, Germany, Lithuania, Estonia, Hungary, Bulgaria
Celldex Therapeutics

Active, not recruiting

A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria

Chronic Spontaneous Urticaria

Spain, United States, Poland, Georgia, South Africa, Bulgaria, Hungary, Estonia, Germany
Biogen
Denali Therapeutics Inc.

Terminated

A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (LIGHTHOUSE)

Parkinson Disease

United States, Italy, Spain, Germany, France, United Kingdom
Idorsia Pharmaceuticals Ltd.

Completed

Single Oral Dose of 4 mg Cenerimod in Healthy Japanese and Caucasian Subjects

Healthy Volunteers

United States
Alzheon Inc.
Quotient Clinical

Completed

Multiple Ascending Dose Study of ALZ-801

Alzheimer Disease

United Kingdom
GlaxoSmithKline

Completed

To Investigate If Single Doses Of GSK618334 Are Safe And To Investigate Blood Levels Of GSK618334

Substance Dependence

United Kingdom
Beech Tree Labs, Inc.
Norwich Clinical Research Associates Ltd.; Hill Top Research

Completed

Evaluation of Cold Sore Treatments on Ultra Violet (UV) Induced Cold Sores

Oral Herpes Simplex

United States
Beech Tree Labs, Inc.
Norwich Clinical Research Associates Ltd.

Completed

Safety and Efficacy Study of a New Treatment for Recurrent Symptoms of Oral Herpes Virus Infection

Oral Herpes Simplex

United States
Novartis Pharmaceuticals

Recruiting

A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis

Aortic Stenosis

Switzerland, Canada, Israel, United States, United Kingdom
Midnight Pharma, LLC

Completed

Almorexant (ACT-078573) in Elderly Subjects With Chronic Primary Insomnia

Chronic Primary Insomnia

United States
Syneos Health

Recruiting

First-in-Human Study of VB0004 in Healthy Subjects and to Patients With Mild to Moderate Hypertension With Low Cardiovascular Risk

Hypertension

Australia
Karyopharm Therapeutics Inc
GOG Foundation; Israeli Society of Gynecologic Oncology; Belgium and Luxembourg... and other collaborators

Active, not recruiting

Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO] (ENGOT-EN5)

Endometrial Cancer

United States, China, Israel, Spain, Belgium, Germany, Greece, Czechia, Italy, Canada
Institut de Recherches Internationales Servier

Active, not recruiting

Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)

Recurrent Glioma | Grade 2 Glioma | Residual Glioma

United States, Canada, Spain, Italy, United Kingdom, Switzerland, Israel, Japan, Netherlands, Germany, France
Novartis Pharmaceuticals

Completed

Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease

Cushings Disease

United States, Canada, Italy, India, Japan, Austria, Netherlands, Spain, Korea, Republic of, Germany, Thailand, France, Bulgaria, Turkey, Colombia, China, Argentina, Russian Federation, United Kingdom
Nathura S.p.A
Evidilya S.r.l.

Completed

A New Class IIb MD in Proctological Disorders

Proctological Disorders

Italy
Regeneron Pharmaceuticals

Completed

Study to Assess the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of a Single Dose of REGN5713-5714-5715 in Healthy Adult Participants

Healthy Volunteers | Birch Pollen Allergy

Belgium
Kubota Vision Inc.
Otsuka Pharmaceutical Co., Ltd.

Completed

Safety and Tolerability of Repeat Doses of ACU-4429 in Healthy Subjects

Healthy

United States
Durata Therapeutics Inc., an affiliate of Allergan...

Completed

Single Dose vs. Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections

Abscess | Cellulitis | Surgical Site Infection | Wound Infection

United States, Bulgaria, Croatia, Estonia, Georgia, Hungary, Latvia, Romania, Russian Federation, Serbia, South Africa, Ukraine
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Completed

Evaluation of 611 in Chinese Adults With Moderate to Severe Atopic Dermatitis

Dermatitis, Atopic

China
Takeda

Completed

Single-Dose Study of MT203

Healthy Volunteers

Japan
Bristol-Myers Squibb

Recruiting

A Study to Evaluate the Safety, Tolerability and Drug Levels of BMS-986454 in Healthy Participants

Healthy Participants

United Kingdom
Bristol-Myers Squibb

Active, not recruiting

A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis

Psoriasis

United States, Australia, Canada, Japan, United Kingdom
Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986325 in Healthy Japanese Participants

Healthy Volunteers

United States
Bristol-Myers Squibb

Terminated

A Phase 1, First-in-Human Study of BMS-986421 in Healthy Participants

Healthy Participants

United States
Bristol-Myers Squibb

Withdrawn

A Single and Multiple Ascending Dose Study of BMS-986318 in Healthy Participants

Healthy Participants

United States
Bristol-Myers Squibb

Completed

A Study to Test the Effects of BMS-986036 on the Body in Healthy Japanese and Non-Japanese Subjects

Metabolics

United States
Bristol-Myers Squibb

Completed

Safety and Tolerability Study of BMS-986177 in Healthy Subjects

Thrombosis

Belgium
Bristol-Myers Squibb

Completed

Crossover Post-herpetic Neuralgia (PHN)

Post-Herpetic Neuralgia (PHN)

United States, France
Bristol-Myers Squibb

Completed

Safety, Pharmacokinetics and Pharmacodynamics Study to Evaluate BMS-830216 in Obese Subjects

Obesity

United States
Bristol-Myers Squibb

Completed

BMS-741672 for Diabetic Neuropathic Pain

Neuropathic Pain

United States
Bristol-Myers Squibb

Completed

A Phase II, Multicenter, Double Blind, Placebo-Controlled Safety, Tolerability Study of BMS-708163 in Patients With Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

Sweden, United States, Denmark, Finland
Bristol-Myers Squibb

Completed

Randomized, Placebo-Controlled, Double-Blind, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-963272 in Healthy Subjects

Healthy

United States
Bristol-Myers Squibb
Solvay Pharmaceuticals

Terminated

Multiple-dose Study to Evaluate the Efficacy, Safety and Pharmacokinetics of BMS-646256 in Obese Subjects

Obesity

United States
Biogen

Enrolling by invitation

A Study to Evaluate the Continuous Safety and Efficacy of Litifilimab (BIIB059) in Adults With Active Systemic Lupus Erythematosus (EMERALD)

Systemic Lupus Erythematosus (SLE)

Spain, Bulgaria, United States, China, Belgium, Serbia, Mexico, Korea, Republic of, Chile, Argentina, Poland, Brazil, Japan, Romania, Colombia, Hungary, Czechia, United Kingdom, Taiwan, Philippines, Israel, France
GlaxoSmithKline

Completed

Safety, Tolerability and Pharmacokinetics of GSK3923868 Inhalation Powder in Healthy Participants and Stable Asthmatics

Pulmonary Disease, Chronic Obstructive

United Kingdom
GTx

Withdrawn

Durability Extension Study to Assess Clinical Activity and Safety of Enobosarm (GTx-024) in Stress Urinary Incontinence

Stress Urinary Incontinence

United States
AstraZeneca

Completed

Study With CIN-107 Following Multiple Oral Ascending Doses in Healthy Subjects

Hypertension

United States
Boehringer Ingelheim

Completed

A Study to Test How Healthy Women Tolerate Different Doses of BI 1819479

Healthy

Germany
Cyclerion Therapeutics

Terminated

Study of IW-1701, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Type I or II Achalasia

Achalasia

United States
Boehringer Ingelheim

Completed

Single Rising Dose Study of BI 135585 XX in Health Asian Male Volunteers.

Healthy

Korea, Republic of
Panacea Biotec Ltd

Unknown

Study Of Single Ascending Doses Of PBL 1427 In Healthy Volunteers

Diabetes Mellitus

India
Vertex Pharmaceuticals Incorporated

Completed

Study of VX-985 in Subjects With Chronic Hepatitis C

Chronic Hepatitis C

United States
National Taiwan University Hospital

Unknown

mCIMT and Eye Patching for Neglect Rehabilitation Post Stroke: A Longitudinal Study of Separate and Combined Effects

Stroke | Hemispatial Neglect

Taiwan
Washington University School of Medicine
Eli Lilly and Company; Hoffmann-La Roche; Avid Radiopharmaceuticals; National Institute... and other collaborators

Recruiting

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001 (DIAN-TU)

Dementia | Alzheimers Disease | Alzheimers Disease, Familial

United States, Canada, Italy, Argentina, Australia, Colombia, France, Ireland, Mexico, Netherlands, Puerto Rico, Spain, United Kingdom, Brazil, Japan, Germany
BeiGene

Withdrawn

Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Treatment in Participants With Hepatocellular Carcinoma

Hepatocellular Carcinoma
Novartis Pharmaceuticals

Active, not recruiting

Efficacy and Safety of Inclisiran as Monotherapy in Chinese Adults With Low or Moderate ASCVD Risk and Elevated Low-density Lipoprotein Cholesterol. (V-Mono China)

Primary Hypercholesterolemia or Mixed Dyslipidemia

China

Search clinical trials for: Placebo (Matching with BMS-919373)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Kingdom

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations